바이오인

 

 

 

Private investment in the US medical technology (medtech) industry has remained strong over the past 18 months, despite a precipitous drop in public equity funding this year due to the global credit crunch. At the same time, venture capital remained strong — setting a new record in 2007 and maintaining a blistering pace in 2008 — and deal making was very active amid strong interest from a broadening base of buyers. 301 US-headquartered, publicly traded medtech companies produced solid growth in revenues and earnings, driven by continued innovation and heightened demand brought by emerging medical and demographic trends.

 

In “Pulse of the industry: US medical technology report 2008”, our first-ever report on the industry’s performance, we examine the current state of the industry and its outlook. You will find critical insights and detailed analysis on of many of the fundamental drivers shaping the industry:

 

□ Financing
□ Mergers and acquisitions
□ Financial performance
□ Public policy

 

High growth potential in the global healthcare economy suggests that the demand for medical technology products should be robust in years ahead. Still, the road ahead is littered with risks and challenges, which include growing pricing pressures from governments and third-party insurers, increased regulatory oversight, and product safety concerns and new regulations, which are limiting traditional methods for cooperating with physicians on product development and refinement.